Michael Kaseta Sells 3,000 Shares of Liquidia (NASDAQ:LQDA) Stock

Liquidia Corporation (NASDAQ:LQDA) CFO Michael Kaseta sold 3,000 shares of the firm’s stock in a transaction that occurred on Tuesday, April 14th. The stock was sold at an average price of $40.00, for a total transaction of $120,000.00. Following the completion of the sale, the chief financial officer owned 405,775 shares in the company, valued at $16,231,000. This represents a 0.73% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Michael Kaseta also recently made the following trade(s):

• On Wednesday, April 15th, Michael Kaseta sold 139,390 shares of Liquidia stock. The stock was sold at an average price of $40.14, for a total transaction of $5,595,114.60.
• On Monday, April 13th, Michael Kaseta sold 18,958 shares of Liquidia stock. The stock was sold at an average price of $38.37, for a total transaction of $727,418.46.
• On Friday, April 10th, Michael Kaseta sold 23,821 shares of Liquidia stock. The stock was sold at an average price of $40.14, for a total transaction of $956,174.94.
• On Thursday, April 9th, Michael Kaseta sold 133,789 shares of Liquidia stock. The stock was sold at an average price of $40.24, for a total transaction of $5,383,669.36.

Liquidia Stock Down 4.7%

LQDA opened at $39.47 on Friday. The company has a current ratio of 2.01, a quick ratio of 1.84 and a debt-to-equity ratio of 2.97. Liquidia Corporation has a 1-year low of $11.85 and a 1-year high of $46.67. The company has a market capitalization of $3.48 billion, a PE ratio of -47.55 and a beta of 0.45. The firm’s 50 day simple moving average is $36.55 and its two-hundred day simple moving average is $33.26.

Liquidia (NASDAQ:LQDA) last released its quarterly earnings results on Thursday, March 5th. The company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.08 by $0.07. Liquidia had a negative net margin of 43.53% and a negative return on equity of 209.33%. The business had revenue of $92.02 million for the quarter, compared to the consensus estimate of $87.49 million. The firm’s revenue was up 3072.4% compared to the same quarter last year. As a group, equities analysts forecast that Liquidia Corporation will post -1.51 EPS for the current year.

Liquidia News Roundup

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Earnings beat and improving near‑term fundamentals — Liquidia reported quarterly revenue and EPS above consensus, which supports the company’s growth thesis and likely attracted buyer interest ahead of the pullback. MarketBeat: Liquidia Stock
• Positive Sentiment: Analyst support remains constructive — several firms have raised price targets or reiterated buy/overweight opinions recently, providing research‑driven demand that can limit downside. MarketBeat: Analyst Coverage
• Neutral Sentiment: High institutional ownership (~64.5%) — large holders can stabilize the share price; insider sales don’t automatically become sustained selling if institutions remain supportive. MarketBeat: Institutional Holdings
• Negative Sentiment: Concentrated insider selling by C‑suite — multiple sizable sales from CFO Michael Kaseta (including multi‑hundred‑thousand and multi‑million dollar blocks) have been disclosed and are likely the main reason shares pulled back today; the volume and visibility of these sales can damage sentiment. InsiderTrades: Kaseta Sale
• Negative Sentiment: CEO and other officers also sold under 10b5‑1 plans — Roger Jeffs disclosed multi‑date sales (including a 25,000‑share block), reinforcing the perception of distributed insider exits that can cap near‑term upside even if planned. SEC Filing: Jeffs Sale

Analyst Ratings Changes

Several research firms have weighed in on LQDA. Jefferies Financial Group increased their price target on shares of Liquidia from $45.00 to $55.00 and gave the stock a “buy” rating in a research report on Tuesday, January 13th. Wall Street Zen upgraded shares of Liquidia from a “hold” rating to a “buy” rating in a research report on Saturday, March 7th. Raymond James Financial reiterated a “strong-buy” rating on shares of Liquidia in a research report on Thursday, March 5th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research report on Thursday, January 22nd. Finally, BTIG Research increased their price target on shares of Liquidia from $49.00 to $50.00 and gave the stock a “buy” rating in a research report on Thursday, March 5th. Two investment analysts have rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $43.44.

Institutional Trading of Liquidia

Institutional investors and hedge funds have recently modified their holdings of the company. Federated Hermes Inc. bought a new stake in shares of Liquidia during the 3rd quarter valued at $7,290,000. Caprock Group LLC bought a new stake in shares of Liquidia during the 3rd quarter valued at $37,114,000. Farallon Capital Management LLC increased its holdings in Liquidia by 102.1% in the 3rd quarter. Farallon Capital Management LLC now owns 8,565,638 shares of the company’s stock valued at $194,783,000 after acquiring an additional 4,326,876 shares during the last quarter. Apis Capital Advisors LLC bought a new stake in Liquidia in the 3rd quarter valued at $9,569,000. Finally, Campbell & CO Investment Adviser LLC bought a new stake in Liquidia in the 3rd quarter valued at $2,026,000. 64.54% of the stock is currently owned by institutional investors.

Liquidia Company Profile

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).